TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07444450: A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvo

Sponsor: Biogen · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 42 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07444450 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07444450 Rescue Dossier →